# Hope Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hope-medicine

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.hopemedinc.com
- Total disclosed funding: $84M
- Latest round: Series B (Feb 7, 2024)
- Investors on record: 10

## About

Established in 2018 and based in Shanghai, China, Hope Medicine is a biopharmaceutical company that focuses on the development of drugs targeting prolactin receptors and novel antibodies. It has partnerships with Nanjing JiangBei New Area, Bayer, and other companies. The research and development bases and offices have been set up in Beijing, Shanghai, and Nanjing. The founder and CSO, Ruiping Xiao, is the founding director and chair professor of the Institute of Molecular Medicine of Peking University. In 2022, HMI-115 has been approved for Phase II clinical trials in China for the treatment of endometriosis. In February 2024, the company raised series B+ funding for CNY 200 million.

The company is committed to the research, development, and industrialization of prolactin. It has developed a potential first-in-class human antibody (HMI-115) targeting the prolactin receptor, which can be used for the treatment of endometriosis, androgenic alopecia, and other diseases with dysregulated prolactin signaling. The pipelines also include GPCR antagonists, Kinase inhibitors, etc.

The company will use the series B+ funds for the research and development of the core pipeline, HMI-115 monoclonal antibody, two ongoing international clinical phase II studies, and other product lines.

## Funding rounds

- Series B, Feb 7, 2024, $28M — Qiming Venture Partners, Sinovation Ventures, Trustbridge Partners, VMS Asset Management, Grand Flight Investment, Jinkong Qiyuan Capital, Ennovation Ventures, HCCD, Beijing Zhongyin Investment
- Series B, May 6, 2021, $56M — Qiming Venture Partners, Sinovation Ventures, Trustbridge Partners, HighLight Capital, Grand Flight Investment
- Series A, Apr 8, 2019 — Trustbridge Partners

## Investors

- Trustbridge Partners (https://capitalatlas.ai/funds/trustbridge-partners) — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Grand Flight Investment (https://capitalatlas.ai/funds/grand-flight-investment) — Series B
- VMS Asset Management (https://capitalatlas.ai/funds/vms-asset-management) — Series B
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series B
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series B
- HCCD — Series B
- Beijing Zhongyin Investment — Series B